文献速递青光眼

辛二酰苯胺异羟肟酸(SAHA)维持滤过泡效应的分子机制

Molecular Mechanisms Underlying the Filtration Bleb-Maintaining Effects of Suberoylanilide Hydroxamic Acid (SAHA).
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究以人结膜成纤维细胞(HConFs)为对象,先用SAHA预处理再给予TGF-β2,通过基因芯片筛选、基因本体分析、Western blot、多重免疫检测和管腔形成实验探讨SAHA维持滤过泡的分子机制。结果显示SAHA部分抑制Smad2、Smad3和Akt磷酸化,并强力抑制TGF-β2驱动的细胞增殖、肌成纤维细胞分化、收缩、细胞外基质产生和血管生成细胞因子表达,其处理后的上清液可抑制管腔形成。作者认为SAHA部分通过抑制Smad和非Smad TGF-β信号通路抑制血管生成和结膜成纤维细胞活化,为SAHA作为调节青光眼滤过术后瘢痕形成的新型候选药物提供了体外分子依据。

要点

  • SAHA在TGF-β2存在时改变TGF-β受体信号通路、细胞增殖、细胞外基质组织、炎症反应和血管生成相关基因表达。
  • SAHA部分抑制Smad2、Smad3和Akt磷酸化。
  • SAHA预处理强力抑制TGF-β2驱动的增殖、肌成纤维细胞分化、收缩、ECM产生和血管生成细胞因子表达,其处理后的HConFs上清液抑制管腔形成。

核心结论

  • SAHA部分通过抑制Smad和非Smad TGF-β信号通路抑制血管生成和结膜成纤维细胞活化。
  • 本体外研究为SAHA维持滤过泡效应的分子基础提供了新证据,SAHA是调节青光眼滤过术后瘢痕形成的新型候选药物。

研究设计与样本

  • 体外研究:人结膜成纤维细胞(HConFs)经SAHA预处理后再给予TGF-β2处理。
  • 采用基因芯片筛选、基因本体(GO)分析、Western blot、多重免疫检测和管腔形成实验(人脐静脉内皮细胞)。

主要发现

  • GO分析显示SAHA在TGF-β2存在时诱导TGF-β受体信号通路、细胞增殖、细胞外基质组织、炎症反应和血管生成相关基因表达改变。
  • 体外实验显示SAHA部分抑制Smad2、Smad3和Akt的磷酸化。
  • SAHA预处理强力抑制TGF-β2驱动的细胞增殖、肌成纤维细胞分化、收缩、ECM产生和血管生成细胞因子表达。
  • 经SAHA处理的HConFs上清液抑制管腔形成。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Suberoylanilide hydroxamic acid (SAHA) has been shown to support the maintenance of experimental filtration blebs in animal models. This study was performed to investigate the molecular mechanisms underlying the bleb-maintaining effects of SAHA in modulating wound healing activities of conjunctival fibroblasts. METHODS: Human conjunctival fibroblasts (HConFs) were pretreated with SAHA before treatment with TGF-β2. Microarray-based screening was used to investigate the gene expression profiles. Gene ontology (GO) analysis was conducted to categorize the gene functions. The expression of TGF-β-induced signaling molecules, α-smooth muscle actin, and extracellular matrix (ECM) proteins were evaluated by Western blot analyses. Multiplex immunoassay was performed to evaluate supernatant cytokine concentrations. Tube formation assay was used to evaluate angiogenesis using human umbilical vein endothelial cells. RESULTS: GO analysis showed that SAHA, in the presence of TGF-β2, induced changes in expression of genes involved in the TGF-β receptor signaling pathway, cell proliferation, extracellular matrix organization, inflammatory responses, and angiogenesis. Subsequent in vitro experiments showed that SAHA partly inhibited the phosphorylation of Smad2, Smad3, and Akt. SAHA pretreatment potently suppressed TGF-β2-driven cell proliferation, myofibroblast differentiation, contraction, ECM production, and angiogenic cytokine expression. The supernatant of HConFs treated with SAHA inhibited tube formation. CONCLUSIONS: SAHA has been shown to suppress angiogenesis and activation of conjunctival fibroblasts partly via inhibition of Smad and non-Smad TGF-β signaling. This in vitro study provides new evidence for the molecular basis of the potential bleb-maintaining effects of SAHA, a novel candidate drug in modulating scar formation after glaucoma filtration surgery.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Futakuchi A, Inoue T, Fujimoto T, et al. Molecular Mechanisms Underlying the Filtration Bleb-Maintaining Effects of Suberoylanilide Hydroxamic Acid (SAHA). Invest Ophthalmol Vis Sci. 2017. PMID: 28448670. doi:10.1167/iovs.16-21403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。